Interprofessional Perspectives on Managing Immune-Related Adverse Events

Released On
November 15, 2021

Expires On
November 15, 2022

Media Type

Completion Time
1.5 hours


Breast Cancer, Lung Cancer, Lymphoma, Multiple Myeloma, Oncology, Prostate Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the American Academy of CME, Inc.


Supported in part by an independent education grant from Merck.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.5 Contact Hours (0.15 CEUs)
  • Nurses — 1.50 Contact Hours (1.50 pharmacotherapeutic contact hours)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity will reach the interprofessional care team of physicians, nurses and pharmacists who care for patients undergoing immunotherapy treatments.

Program Overview

The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaboration among members of the oncology care team is necessary to ensure that all healthcare providers, patients, and caregivers are educated about irAEs and their management. For all members of the team to support optimal outcomes, clinicians need to continue to enhance their knowledge and skills regarding the latest guidelines and treatment.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe key processes that underlie immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T-cell (CAR-T) therapy
  • Identify early signs of novel irAEs associated with ICIs and CAR-T therapies
  • Apply guideline-recommended strategies for monitoring and managing novel irAES associated with ICIs and CAR-T therapy
  • Educate patients and caregivers to recognize early signs of irAEs in patients treated with ICIs or CAR-T therapies and when to seek medical attention
  • Improve clinician confidence in managing irAEs through interprofessional collaboration


Paolo Caimi, MD

Staff Physician, Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

Marcus Flores, Pharm.D., BCPS, BCOP

Clinical Pharmacist, Oncology
Hackensack Meridian Health Cancer Care
Jersey Shore University Medical Center
Neptune, NJ

Laura Wood, RN, MSN, OCN

Renal Cancer Research Coordinator Cleveland Clinic
Taussig Cancer Institute
Cleveland, Ohio

Joint Accreditation Statement

In support of improving patient care, American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

American Academy of CME, Inc., designates this enduring educational activity for 1.50 ANCC contact hours (1.50 pharmacotherapeutic contact hours).

Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.5 contact hours.

Pharmacist Accreditation Statement

This activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-22-005-H01-P, Application

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures of Conflicts of Interest

Laura Wood, RN, MSN, OCN

  • Advisory Board - Scientific Information: Eisai, nursing advisory board for education and adverse event management
  • Promotional Speaker's Bureau : AVEO, Bristol Myers Squibb, EMD Serono, Merck, Pfizer

Marcus Flores, PharmD, BCPS, BCOP, no relevant financial disclosures

Paolo Caimi, MD

  • Advisory Board/Marketing Purposes: ADC Therapeutics, Verastem
  • Advisory Board/Scientific Information: ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetics, Amgen
  • Consultant/Clinical Trial Design: ADC Therapeutics, TG Therapeutics
  • Grant Recipient/Research Support: Genentech, ADC Therapeutics, TG Therapeutics
  • Spouse: Intellectual Property/Patients: XaTEC


Planning Committee
John JD Juchniewicz, MCIS, CHCP, FACEHP, Natalie Kirkwood RN, BSN, JD, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any ineligible companies.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the activity assessment (scoring at least 70%) and submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

American Academy of CME, Inc requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

This activity mentions tremelimumab, which has no trade name and is not FDA-approved but has been assigned an orphan drug designation by the FDA.


This activity is designed for educational purposes. The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.


For more information about the American Academy of CME privacy policy, please access

Contact Information

For CME questions please contact: